Keyphrases
Treatment Outcome
100%
Lung Cancer
100%
Genomic Medicine
100%
EGFR mutation
100%
National Network
100%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
75%
Compound mutation
37%
Exon 20 Insertion
37%
Point mutation
25%
Highly Heterogeneous
25%
Chemotherapy
25%
Epidermal Growth Factor Receptor
25%
Systemic Treatment
25%
L861Q
25%
G719X
25%
Single-point mutation
25%
Germany
12%
Detrimental Effects
12%
Exon 20
12%
One-group
12%
Treatment Response
12%
Cancer Cases
12%
Real-life Cohort
12%
Immune Checkpoint Inhibitors
12%
Response to Treatment
12%
High Efficacy
12%
TP53 mutation
12%
Non-small Cell Lung Cancer (NSCLC)
12%
Non-small Cell Lung Cancer Patients
12%
Tyrosine Kinase Inhibitor
12%
Clinical Follow-up
12%
Significant Trend
12%
Exon 18
12%
Mutation-based
12%
Uncommon mutation
12%
Recurrent mutation
12%
Exon 19
12%
Inhibitor Sensitivity
12%
S768I
12%
Lung Cancer Classification
12%
L858R mutation
12%
Exon 19 Deletion mutation
12%
Clinical Outcomes
12%
Single Compounds
12%
Retrospective multicenter Study
12%
Medicine and Dentistry
Medicine
100%
Lung Cancer
100%
Epidermal Growth Factor Receptor
100%
Exon
70%
Epidermal Growth Factor Receptor Kinase Inhibitor
60%
Point Mutation
20%
Systemic Therapy
20%
Non Small Cell Lung Cancer
20%
Cancer Classification
10%
Treatment Response
10%
Immune Checkpoint Inhibitor
10%
Tyrosine-Kinase Inhibitor
10%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
100%
Genomics
100%
Exon
43%
Receptor Tyrosine Kinase Inhibitors
37%
Point Mutation
12%
Immune Checkpoints
6%
Tyrosine Kinase Inhibitor
6%
Cancer Classification
6%